FDA Approves Kirsty as First Interchangeable Insulin Aspart Biosimilar

July 15, 2025

The FDA has approved Kirsty, the first interchangeable insulin aspart biosimilar, enhancing access to affordable diabetes care for millions.

White Paper Offers Tips for Sustaining Biosimilar Progress, Avoiding a Market Void

July 15, 2025

BioRationality: How the FDA Can Bypass Congress to Change Biosimilar Guidance

July 14, 2025

Balancing Cost Savings With Clinical Practice for Multiple Myeloma Biosimilars: Tyler Sandahl, PharmD

July 14, 2025

Inpatient Biosimilar Use Grows, Offering Cost-Saving Opportunities for Health Systems

July 11, 2025

BioRationality: The Do’s and Don’ts of Adding Novelty to Biosimilars Development

May 30th 2023

By Sarfaraz K. Niazi, PhD

Article

In his latest column, Sarfaraz K. Niazi, PhD, went over some best practices for implementing innovative solutions for the purposes of streamlining biosimilar development.

Amgen’s Stelara Biosimilar Delayed Until 2025 After Settling With J&J

May 29th 2023

By Skylar Jeremias

Article

Amgen has settled with Johnson & Johnson (J&J) over the former’s ustekinumab biosimilar referencing Stelara, delaying the projected launch of the candidate from late 2023 to January 2025.

What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends

May 28th 2023

By Skylar Jeremias

Podcast

On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.

Study: Biosimilar Market Share Has Increased Over Time in All European Markets

May 27th 2023

By Deana Ferreri, PhD

Article

Biosimilar market penetration has been slower than that of generics but the market share of biosimilars has grown over time, according to the authors of a study on biosimilar use in the European Union (EU).

The Top 5 Biosimilar Articles for the Week of May 22

May 26th 2023

By Justina Petrullo

Video

Here are the top 5 biosimilar articles for the week of May 22, 2023.

Biosimilar Acceptance Takes Time but Policy Intervention Is Needed, Panelists Say

May 25th 2023

By Skylar Jeremias

Article

A group of panelists at Asembia 2023 shared the bigger role that pharmacists, payers, and providers can play in growing biosimilar acceptance and championing policy changes that boost biosimilar utilization.

FDA Approves Celltrion’s Yuflyma, the Ninth Adalimumab Biosimilar

May 24th 2023

By Skylar Jeremias

Article

Celltrion Healthcare announced that the FDA has approved Yuflyma (adalimumab-aaty) as the ninth biosimilar referencing Humira (adalimumab).

Recent Findings Highlight Need for Policy Changes for Biosimilars, Follow-on Biologics

May 23rd 2023

By Justina Petrullo

Article

Findings from a recent study emphasize the need for improvement and changes regarding follow-on biologics and biosimilars in the global biosimilar market.

Celltrion Launches Biobetter in Brazil, Shares Phase 3 Plan for MS Biosimilar

May 22nd 2023

By Skylar Jeremias

Article

As Celltrion Healthcare announces the launch of the biobetter version of Remsima (Remsima SC) in Brazil, the company shared the phase 3 plan for its ocrelizumab biosimilar to treat multiple sclerosis (MS).

Dr Fran Gregory: What Can We Learn From Biosimilar Use in Other Countries?

May 21st 2023

By Pearl Steinzor

Video

Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses how the use of biosimilars in other countries strengthens the acceptance and approval of these products in the United States.